目的观察臌胀片在乙肝 e 抗原(HBeAg)阳性慢性乙型病毒性肝炎治疗中的减毒增效作用。方法将80例HBeAg阳性慢性乙型肝炎患者随机分为治疗组(臌胀片联合替比夫定)和对照组(替比夫定),均治疗1年,观察治疗前后2组患者丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、乙肝病毒-DNA(HBV-DNA)阴转率、HBeAg阴转率、HBeAg/HBeAb血清学转换率、血清肌酸激酶(CK)水平及安全性。结果治疗48周后,治疗组ALT、AST、HBV DNA阴转率、HBeAg阴转率及HBeAg/HBeAb血清学转换率均优于对照组(P＜0.05)。2组患者均有CK升高,其中治疗组13例(32.5%),对照组24例(60.0%),2组比较差异有统计学意义(P＜0.05)。结论臌胀片与替比夫定联合用药后,其减毒增效作用显著。%Objective To observe the attenuated and synergistic effect of meteorism tablets in treating HBeAg-positive chronic hepatitis B patients. Methods Eighty patients of HBeAg-positive chronic hepatitis B were randomly divided into treatment group (meteorism tablets combined with telbivudine) and control group (telbivudine), and treated for one year. The changes of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the negative rate of HBV-DNA, the negative rate of HBeAg, HBeAg/HbeAb serological conversion rate, creatine kinase (CK) before and after treatment, and safety were observed. Results After treatment, biochemical response, virological response and HBeAg serological response was more significant in the treatment group than that in the control group (P<0.05). The percetage of patients with elevated CK in the treatment group was significantly lower than that in the control group (32.5% vs 60%, P<0.05). Conclusion Meteorism tablets combined with telbivudine has attenuated and synergistic effect in treating HBeAg-positive chronic hepatitis B patients.
展开▼
